LAPTM4B gene copy number gain is associated with inferior response to anthracycline-based chemotherapy in hormone receptor negative breast carcinomas

Rusz, O [Rusz, Orsolya (onkológia), author] Department of Oncotherapy (USZ / ASZMS); Papp, O*; Vizkeleti, L [Vízkeleti, Laura (molekuláris bioló...), author] MTA-SE-NAP B Brain Metastasis Research Group (SU / FM / I / IIDP); Molnar, BA; Bende, KC; Lotz, G [Lotz, Gábor (Hepatológia, path...), author] II. Department of Pathology (SU / FM / I); Acs, B [Ács, Balázs (patológia, onkológia), author] II. Department of Pathology (SU / FM / I); Kahan, Z [Kahán, Zsuzsanna (Elméleti orvostud...), author] Department of Oncotherapy (USZ / ASZMS); Szekely, T [Székely, Tamás (patológia), author] II. Department of Pathology (SU / FM / I); Bathori, A; Szundi, C; Kulka, J [Kulka, Janina (Emlőpathológia), author] II. Department of Pathology (SU / FM / I); Szallasi, Z [Szállási, Zoltán (Onkológia, dagana...), author] MTA-SE-NAP B Brain Metastasis Research Group (SU / FM / I / IIDP); Tokes, AM ✉ [Tőkés, Anna-Mária (Emlőpathológia és...), author] II. Department of Pathology (SU / FM / I)

English Scientific Article (Journal Article)
  • SJR Scopus - Pharmacology (medical): Q1
Identifiers
Subjects:
    PURPOSE: To determine the associations between lysosomal-associated transmembrane protein 4b (LAPTM4B) gene copy number and response to different chemotherapy regimens in hormone receptor negative (HR-) primary breast carcinomas. PATIENTS AND METHODS: Two cohorts were analyzed: (1) 69 core biopsies from HR-breast carcinomas treated with neoadjuvant chemotherapy (anthracycline based in 72.5% of patients and non-anthracycline based in 27.5% of patients). (2) Tissue microarray (TMA) of 74 HR-breast carcinomas treated with adjuvant therapy (77.0% of the patients received anthracycline, 17.6% of the patients non-anthracycline-based therapy, and in 5.4% of the cases, no treatment data are available). Interphase FISH technique was applied on pretreatment core biopsies (cohort I) and on TMAs (cohort II) using custom-made dual-labelled FISH probes (LAPTM4B/CEN8q FISH probe Abnova Corp.). RESULTS: In the neoadjuvant cohort in the anthracycline-treated group, we observed a significant difference (p = 0.029) of average LAPTM4B copy number between the non-responder and pathological complete responder groups (4.1 +/- 1.1 vs. 2.6 +/- 0.1). In the adjuvant setting, the anthracycline-treated group of metastatic breast carcinomas was characterized by higher LAPTM4B copy number comparing to the non-metastatic ones (p = 0.046). In contrast, in the non-anthracycline-treated group of patients, we did not find any LAPTM4B gene copy number differences between responder vs. non-responder groups or between metastatic vs. non-metastatic groups. CONCLUSION: Our results confirm the possible role of the LAPTM4B gene in anthracycline resistance in HR- breast cancer. Analyzing LAPTM4B copy number pattern may support future treatment decision.
    Citation styles: IEEEACMAPAChicagoHarvardCSLCopyPrint
    2021-12-04 08:51